The company’s product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, which is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients.
The company announced in January that it has entered into a discovery collaboration in the field of oncology with Genentech, a member of the Roche Group, focused on discovering and developing small-molecule drugs that modulate transcription factor targets selected by Genentech. Kronos Bio will receive a $20 million upfront payment and could receive up to an additional $554 million in milestone payments.
The target price at Goldman Sachs is $14. The lower $10 consensus target is also well above Friday’s $1.67 per share. Hitting the Goldman Sachs target would be a gain of 735%.
Wheels Up
Flying private has exploded since the start of the pandemic in 2020, and that growth may remain for years. Wheels Up Experience Inc. (NYSE: UP) provides private aviation services, primarily in the United States.
The company’s a suite of products and services includes multi-tiered membership programs, on-demand flights across various private aircraft cabin categories, aircraft management, retail and wholesale charter, whole aircraft acquisitions and sales, corporate flight solutions, special missions, signature events and experiences, and commercial travel. It operates a fleet of approximately 1,500 aircraft.
Wheels Up Customers can access membership programs, charter, aircraft management services and whole aircraft sales, as well as unique commercial travel benefits through a strategic partnership with Delta Air Lines. The Wheels Up Services brands also offer freight, safety and security solutions, and managed services to individuals, industry, government and civil organizations.
The Goldman Sachs price target of $3.70 compares with a $3.54 consensus target and a price on Friday of $1.11 a share. Hitting the target would be a 230% gain.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with absolutely no track record or liquidity.
Originally published at 24/7 Wall St.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
